29 results on '"Bloomfield MA"'
Search Results
2. The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls.
- Author
-
Lawn W, Mokrysz C, Lees R, Trinci K, Petrilli K, Skumlien M, Borissova A, Ofori S, Bird C, Jones G, Bloomfield MA, Das RK, Wall MB, Freeman TP, and Curran HV
- Subjects
- Adolescent, Adult, Humans, Cross-Sectional Studies, Case-Control Studies, Anxiety epidemiology, Depression epidemiology, Marijuana Abuse epidemiology, Psychotic Disorders epidemiology
- Abstract
Background: Adolescence is characterised by psychological and neural development. Cannabis harms may be accentuated during adolescence. We hypothesised that adolescents would be more vulnerable to the associations between cannabis use and mental health and addiction problems than adults., Method: As part of the 'CannTeen' study, we conducted a cross-sectional analysis. There were 274 participants: split into groups of adolescent users ( n = 76; 16-17 years old) and controls ( n = 63), and adult users ( n = 71; 26-29 years old) and controls ( n = 64). Among users, cannabis use frequency ranged from 1 to 7 days/week, while controls had 0-10 lifetime exposures to cannabis. Adolescent and adult cannabis users were matched on cannabis use frequency (mean=4 days/week). We measured Diagnostic and Statistical Manual (DSM-5) Cannabis Use Disorder (CUD), Beck Depression Inventory, Beck Anxiety Inventory and Psychotomimetic States Inventory-adapted., Results: After adjustment for covariates, adolescent users were more likely to have severe CUD than adult users (odd ratio = 3.474, 95% confidence interval (CI) = 1.501-8.036). Users reported greater psychotic-like symptoms than controls ( b = 6.004, 95% CI = 1.211-10.796) and adolescents reported greater psychotic-like symptoms than adults ( b = 5.509, 95% CI = 1.070-9.947). User-group was not associated with depression or anxiety. No significant interactions between age-group and user-group were identified. Exploratory analyses suggested that cannabis users with severe CUD had greater depression and anxiety levels than cannabis users without severe CUD., Conclusion: Adolescent cannabis users are more likely than adult cannabis users to have severe CUD. Adolescent cannabis users have greater psychotic-like symptoms than adult cannabis users and adolescent controls, through an additive effect. There was no evidence of an amplified vulnerability to cannabis-related increases in subclinical depression, anxiety or psychotic-like symptoms in adolescence. However, poorer mental health was associated with the presence of severe CUD.
- Published
- 2022
- Full Text
- View/download PDF
3. Individual and combined effects of cannabidiol and Δ 9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain.
- Author
-
Wall MB, Freeman TP, Hindocha C, Demetriou L, Ertl N, Freeman AM, Jones AP, Lawn W, Pope R, Mokrysz C, Solomons D, Statton B, Walker HR, Yamamori Y, Yang Z, Yim JL, Nutt DJ, Howes OD, Curran HV, and Bloomfield MA
- Subjects
- Brain, Cannabinoid Receptor Agonists pharmacology, Double-Blind Method, Dronabinol pharmacology, Humans, Cannabidiol pharmacology, Cannabinoids pharmacology, Cannabis, Hallucinogens pharmacology
- Abstract
Background: Cannabidiol (CBD) and Δ
9 -tetrahydrocannabinol (THC) are the two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular, the striatum is implicated in the pathophysiology of several psychiatric disorders, but it is unclear how THC and CBD influence striato-cortical connectivity., Aims: To examine effects of THC, CBD, and THC + CBD on functional connectivity of striatal sub-divisions (associative, limbic and sensorimotor)., Method: Resting-state functional Magnetic Resonance Imaging (fMRI) was used across two within-subjects, placebo-controlled, double-blind studies, with a unified analysis approach., Results: Study 1 ( N = 17; inhaled cannabis containing 8 mg THC, 8 mg THC + 10 mg CBD or placebo) showed strong disruptive effects of both THC and THC + CBD on connectivity in the associative and sensorimotor networks, but a specific effect of THC in the limbic striatum network which was not present in the THC + CBD condition. In Study 2 ( N = 23, oral 600 mg CBD, placebo), CBD increased connectivity in the associative network, but produced only relatively minor disruptions in the limbic and sensorimotor networks., Outcomes: THC strongly disrupts striato-cortical networks, but this effect is mitigated by co-administration of CBD in the limbic striatum network. Oral CBD administered has a more complex effect profile of relative increases and decreases in connectivity. The insula emerges as a key region affected by cannabinoid-induced changes in functional connectivity, with potential implications for understanding cannabis-related disorders, and the development of cannabinoid therapeutics.- Published
- 2022
- Full Text
- View/download PDF
4. Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.
- Author
-
Borissova A, Ferguson B, Wall MB, Morgan CJ, Carhart-Harris RL, Bolstridge M, Bloomfield MA, Williams TM, Feilding A, Murphy K, Tyacke RJ, Erritzoe D, Stewart L, Wolff K, Nutt D, Curran HV, and Lawn W
- Subjects
- Adult, Bayes Theorem, Cooperative Behavior, Double-Blind Method, Female, Hallucinogens blood, Hallucinogens pharmacology, Humans, Male, Middle Aged, N-Methyl-3,4-methylenedioxyamphetamine blood, Social Behavior, Young Adult, Affect drug effects, Empathy drug effects, N-Methyl-3,4-methylenedioxyamphetamine pharmacology, Trust psychology
- Abstract
Background: 3,4-Methylenedioxymethamphetamine (MDMA) is being actively researched as an adjunct to psychotherapy. It may be beneficial to trust, empathy and cooperative behaviour due to its acute prosocial effects., Aim: To test (a) the acute effects of MDMA on measures of empathy, trust and cooperative behaviour, and (b) subacute changes in mood three days after MDMA administration., Methods: Twenty-five participants ( n =7 female), participated in this double-blind, repeated-measures, placebo-controlled experiment. Participants attended two acute sessions, one week apart. Each acute session was followed by a subacute session three days later. Participants received placebo (100 mg ascorbic acid) during one acute session, and MDMA (100 mg MDMA-HCl) at the other, with order counterbalanced. Participants completed the following tasks assessing prosocial behaviour: a trust investment task, a trustworthy face rating task, an empathic stories task, a public project game, a dictator game and an ultimatum game. Participants reported subjective effects. Blood was taken pre-drug, 2 and 4 hours post-drug, and tested for plasma MDMA levels., Results: MDMA acutely increased self-reported 'closeness to others' and 'euphoria' and increased plasma concentrations of MDMA. MDMA did not significantly change task-based empathy, trust or cooperative behaviour. Using Bayesian analyses, we found evidence that MDMA and placebo did not differ in their effects on empathy and cooperative behaviour. MDMA did not significantly change subacute mood and this was supported by our Bayesian analyses., Conclusion: Despite augmentation in plasma MDMA levels and subjective drug effects, we found no increase in prosocial behaviour in a laboratory setting.
- Published
- 2021
- Full Text
- View/download PDF
5. Predictors and rates of PTSD, depression and anxiety in UK frontline health and social care workers during COVID-19.
- Author
-
Greene T, Harju-Seppänen J, Adeniji M, Steel C, Grey N, Brewin CR, Bloomfield MA, and Billings J
- Abstract
Background : Studies have shown that working in frontline healthcare roles during epidemics and pandemics was associated with PTSD, depression, anxiety, and other mental health disorders. Objectives : The objectives of this study were to identify demographic, work-related and other predictors for clinically significant PTSD, depression, and anxiety during the COVID-19 pandemic in UK frontline health and social care workers (HSCWs), and to compare rates of distress across different groups of HCSWs working in different roles and settings. Methods : A convenience sample ( n = 1194 ) of frontline UK HCSWs completed an online survey during the first wave of the pandemic (27 May - 23 July 2020). Participants worked in UK hospitals, nursing or care homes and other community settings. PTSD was assessed using the International Trauma Questionnaire (ITQ); Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9); Anxiety was assessed using the Generalized Anxiety Disorder Scale (GAD-7). Results : Nearly 58% of respondents met the threshold for a clinically significant disorder (PTSD = 22%; anxiety = 47%; depression = 47%), and symptom levels were high across occupational groups and settings. Logistic regression analyses found that participants who were concerned about infecting others, who could not talk with their managers if there were not coping, who reported feeling stigmatized and who had not had reliable access to personal protective equipment (PPE) were more likely to meet criteria for a clinically significant mental disorder. Being redeployed during the pandemic, and having had COVID were associated with higher odds for PTSD. Higher household income was associated with reduced odds for a mental disorder. Conclusions : This study identified predictors of clinically significant distress during COVID-19 and highlights the need for reliable access to PPE and further investigation of barriers to communication between managers and staff., Competing Interests: No potential conflict of interest was reported by the authors., (© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.)
- Published
- 2021
- Full Text
- View/download PDF
6. The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers.
- Author
-
Lawn W, Hill J, Hindocha C, Yim J, Yamamori Y, Jones G, Walker H, Green SF, Wall MB, Howes OD, Curran HV, Freeman TP, and Bloomfield MA
- Subjects
- Adult, Brain Mapping, Cannabidiol administration & dosage, Cannabinoid Receptor Modulators administration & dosage, Cerebral Cortex diagnostic imaging, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Young Adult, Anticipation, Psychological drug effects, Cannabidiol pharmacology, Cannabinoid Receptor Modulators pharmacology, Cerebral Cortex drug effects, Delay Discounting drug effects, Feedback, Psychological drug effects, Motivation drug effects, Reward
- Abstract
Background: Cannabidiol has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that cannabidiol may influence some aspects of reward processing. However, it is unknown whether cannabidiol acutely affects brain function underpinning reward anticipation and feedback., Hypotheses: We predicted that cannabidiol would augment brain activity associated with reward anticipation and feedback., Methods: We administered a single 600 mg oral dose of cannabidiol and matched placebo to 23 healthy participants in a double-blind, placebo-controlled, repeated-measures design. We employed the monetary incentive delay task during functional magnetic resonance imaging to assay the neural correlates of reward anticipation and feedback. We conducted whole brain analyses and region-of-interest analyses in pre-specified reward-related brain regions., Results: The monetary incentive delay task elicited expected brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate and orbitofrontal cortex. However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our regions-of-interest was similar following cannabidiol and placebo. Additionally, our behavioural measures of motivation for reward did not show a significant difference between cannabidiol and placebo., Discussion: Cannabidiol did not acutely affect the neural correlates of reward anticipation and feedback in healthy participants. Future research should explore the effects of cannabidiol on different components of reward processing, employ different doses and administration regimens, and test its reward-related effects in people with psychiatric disorders.
- Published
- 2020
- Full Text
- View/download PDF
7. The effects of psychosocial stress on dopaminergic function and the acute stress response.
- Author
-
Bloomfield MA, McCutcheon RA, Kempton M, Freeman TP, and Howes O
- Subjects
- Adult, Child, Corpus Striatum metabolism, Female, Humans, Male, Positron-Emission Tomography, Young Adult, Dopamine metabolism, Stress, Psychological
- Abstract
Chronic psychosocial adversity induces vulnerability to mental illnesses. Animal studies demonstrate that this may be mediated by dopaminergic dysfunction. We therefore investigated whether long-term exposure to psychosocial adversity was associated with dopamine dysfunction and its relationship to psychological and physiological responses to acute stress. Using 3,4-dihydroxy-6-[
18 F]-fluoro- l -phenylalanine ([18 F]-DOPA) positron emission tomography (PET), we compared dopamine synthesis capacity in n = 17 human participants with high cumulative exposure to psychosocial adversity with n = 17 age- and sex-matched participants with low cumulative exposure. The PET scan took place 2 hr after the induction of acute psychosocial stress using the Montréal Imaging Stress Task to induce acute psychosocial stress. We found that dopamine synthesis correlated with subjective threat and physiological response to acute psychosocial stress in the low exposure group. Long-term exposure to psychosocial adversity was associated with dampened striatal dopaminergic function (p=0.03, d = 0.80) and that psychosocial adversity blunted physiological yet potentiated subjective responses to acute psychosocial stress. Future studies should investigate the roles of these changes in vulnerability to mental illnesses., Competing Interests: MB, RM, MK, TF No competing interests declared, OH Professor Howes has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. Neither Professor Howes nor his family have been employed by or have holdings/a financial stake in any biomedical company., (© 2019, Bloomfield et al.)- Published
- 2019
- Full Text
- View/download PDF
8. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.
- Author
-
Wall MB, Pope R, Freeman TP, Kowalczyk OS, Demetriou L, Mokrysz C, Hindocha C, Lawn W, Bloomfield MA, Freeman AM, Feilding A, Nutt D, and Curran HV
- Subjects
- Adult, Brain diagnostic imaging, Brain drug effects, Cross-Over Studies, Double-Blind Method, Female, Hallucinogens pharmacology, Humans, Magnetic Resonance Imaging, Male, Young Adult, Cannabidiol pharmacology, Dronabinol pharmacology, Marijuana Smoking psychology
- Abstract
Background: Two major constituents of cannabis are Δ
9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC., Aims: We examined the effects of two strains of cannabis and placebo on the human brain's resting-state networks using fMRI., Methods: Seventeen healthy volunteers (experienced with cannabis, but not regular users) underwent three drug treatments and scanning sessions. Treatments were cannabis containing THC (Cann-CBD; 8 mg THC), cannabis containing THC with CBD (Cann+CBD; 8 mg THC + 10 mg CBD), and matched placebo cannabis. Seed-based resting-state functional connectivity analyses were performed on three brain networks: the default mode (DMN; defined by positive connectivity with the posterior cingulate cortex: PCC+), executive control (ECN; defined by negative connectivity with the posterior cingulate cortex: PCC-) and salience (SAL; defined by positive connectivity with the anterior insula: AI+) network., Results: Reductions in functional connectivity (relative to placebo) were seen in the DMN (PCC+) and SAL (AI+) networks for both strains of cannabis, with spatially dissociable effects. Across the entire salience network (AI+), Cann-CBD reduced connectivity relative to Cann+CBD. The PCC in the DMN was specifically disrupted by Cann-CBD, and this effect correlated with subjective drug effects, including feeling 'stoned' and 'high'., Conclusions: THC disrupts the DMN, and the PCC is a key brain region involved in the subjective experience of THC intoxication. CBD restores disruption of the salience network by THC, which may explain its potential to treat disorders of salience such as psychosis and addiction.- Published
- 2019
- Full Text
- View/download PDF
9. The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life.
- Author
-
Froudist-Walsh S, Bloomfield MA, Veronese M, Kroll J, Karolis VR, Jauhar S, Bonoldi I, McGuire PK, Kapur S, Murray RM, Nosarti C, and Howes O
- Subjects
- Adult, Dopamine analysis, Female, Humans, London, Magnetic Resonance Imaging, Male, Positron-Emission Tomography, Brain Injuries complications, Dopaminergic Neurons physiology, Hippocampus pathology, Hippocampus physiopathology
- Abstract
Perinatal brain injuries, including hippocampal lesions, cause lasting changes in dopamine function in rodents, but it is not known if this occurs in humans. We compared adults who were born very preterm with perinatal brain injury to those born very preterm without perinatal brain injury, and age-matched controls born at full term using [18F]-DOPA PET and structural MRI. Dopamine synthesis capacity was reduced in the perinatal brain injury group relative to those without brain injury (Cohen's d = 1.36, p=0.02) and the control group (Cohen's d = 1.07, p=0.01). Hippocampal volume was reduced in the perinatal brain injury group relative to controls (Cohen's d = 1.17, p=0.01) and was positively correlated with striatal dopamine synthesis capacity (r = 0.344, p=0.03). This is the first evidence in humans linking neonatal hippocampal injury to adult dopamine dysfunction, and provides a potential mechanism linking early life risk factors to adult mental illness.
- Published
- 2017
- Full Text
- View/download PDF
10. Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis.
- Author
-
Egerton A, Howes OD, Houle S, McKenzie K, Valmaggia LR, Bagby MR, Tseng HH, Bloomfield MA, Kenk M, Bhattacharyya S, Suridjan I, Chaddock CA, Winton-Brown TT, Allen P, Rusjan P, Remington G, Meyer-Lindenberg A, McGuire PK, and Mizrahi R
- Subjects
- Adult, Canada, Female, Humans, Male, Neostriatum diagnostic imaging, Positron-Emission Tomography, Psychotic Disorders diagnostic imaging, Risk, Schizophrenia diagnostic imaging, Stress, Psychological diagnostic imaging, United Kingdom, Young Adult, Dopamine metabolism, Emigrants and Immigrants, Neostriatum metabolism, Psychotic Disorders metabolism, Schizophrenia metabolism, Stress, Psychological metabolism
- Abstract
Migration is a major risk factor for schizophrenia but the neurochemical processes involved are unknown. One candidate mechanism is through elevations in striatal dopamine synthesis and release. The objective of this research was to determine whether striatal dopamine function is elevated in immigrants compared to nonimmigrants and the relationship with psychosis. Two complementary case-control studies of in vivo dopamine function (stress-induced dopamine release and dopamine synthesis capacity) in immigrants compared to nonimmigrants were performed in Canada and the United Kingdom. The Canadian dopamine release study included 25 immigrant and 31 nonmigrant Canadians. These groups included 23 clinical high risk (CHR) subjects, 9 antipsychotic naïve patients with schizophrenia, and 24 healthy volunteers. The UK dopamine synthesis study included 32 immigrants and 44 nonimmigrant British. These groups included 50 CHR subjects and 26 healthy volunteers. Both striatal stress-induced dopamine release and dopamine synthesis capacity were significantly elevated in immigrants compared to nonimmigrants, independent of clinical status. These data provide the first evidence that the effect of migration on the risk of developing psychosis may be mediated by an elevation in brain dopamine function., (© The Author 2017. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.)
- Published
- 2017
- Full Text
- View/download PDF
11. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
- Author
-
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, and Correll CU
- Subjects
- Brief Psychiatric Rating Scale statistics & numerical data, Humans, Practice Guidelines as Topic, Psychometrics, Randomized Controlled Trials as Topic, Schizophrenia diagnosis, Antipsychotic Agents therapeutic use, Drug Resistance, Schizophrenia drug therapy, Schizophrenic Psychology
- Abstract
Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines., Method: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus., Results: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting of minimum adherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients., Conclusions: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.
- Published
- 2017
- Full Text
- View/download PDF
12. Salience attribution and its relationship to cannabis-induced psychotic symptoms.
- Author
-
Bloomfield MA, Mouchlianitis E, Morgan CJ, Freeman TP, Curran HV, Roiser JP, and Howes OD
- Subjects
- Adult, Brain diagnostic imaging, Brain metabolism, Cannabis adverse effects, Case-Control Studies, Dihydroxyphenylalanine analogs & derivatives, Dopamine metabolism, Female, Humans, Male, Marijuana Abuse diagnostic imaging, Marijuana Abuse metabolism, Neostriatum diagnostic imaging, Neostriatum metabolism, Positron-Emission Tomography, Psychoses, Substance-Induced diagnostic imaging, Psychoses, Substance-Induced etiology, Psychoses, Substance-Induced metabolism, Radiopharmaceuticals, Reward, Young Adult, Marijuana Abuse psychology, Psychoses, Substance-Induced psychology
- Abstract
Background: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity., Method: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K i cer , was measured in 10 users and six controls with 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine positron emission tomography., Results: There was no significant difference in aberrant salience between the groups [F 1,32 = 1.12, p = 0.30 (implicit); F 1,32 = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F 1,15 = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = -0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = -2.05, p = 0.04)., Conclusions: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.
- Published
- 2016
- Full Text
- View/download PDF
13. The effects of Δ 9 -tetrahydrocannabinol on the dopamine system.
- Author
-
Bloomfield MA, Ashok AH, Volkow ND, and Howes OD
- Subjects
- Animals, Behavior, Animal drug effects, Brain cytology, Cell Shape drug effects, Dopaminergic Neurons drug effects, Dopaminergic Neurons metabolism, Dronabinol administration & dosage, Eating drug effects, Humans, Post-Synaptic Density drug effects, Post-Synaptic Density metabolism, Presynaptic Terminals drug effects, Presynaptic Terminals metabolism, Receptor, Cannabinoid, CB1 metabolism, Brain drug effects, Brain metabolism, Dopamine metabolism, Dronabinol pharmacology
- Abstract
The effects of Δ
9 -tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, are a pressing concern for global mental health. Patterns of cannabis use are changing drastically owing to legalization, the availability of synthetic analogues (commonly termed spice), cannavaping and an emphasis on the purported therapeutic effects of cannabis. Many of the reinforcing effects of THC are mediated by the dopamine system. Owing to the complexity of the cannabinoid-dopamine interactions that take place, there is conflicting evidence from human and animal studies concerning the effects of THC on the dopamine system. Acute THC administration causes increased dopamine release and neuron activity, whereas long-term use is associated with blunting of the dopamine system. Future research must examine the long-term and developmental dopaminergic effects of THC., Competing Interests: statement. Dr Bloomfield conducts research funded by the Medical Research Council (UK), the National Institute of Health Research (UK) and the British Medical Association. Dr Ashok conducts research funded by the Medical Research Council (UK) and Kings College London. Dr Volkow is Director of the National Institute on Drug Abuse (USA). Professor Howes conducts research funded by the Medical Research Council (UK), the National Institute of Health Research (UK) and the Maudsley Charity. Professor Howes has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Astra-Zeneca, BMS, Eli Lilly, Jansenn, Lundbeck, Lyden-Delta, Servier, and Roche. Neither Professor Howes nor his family have been employed by or have holdings/a financial stake in any biomedical company.- Published
- 2016
- Full Text
- View/download PDF
14. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses.
- Author
-
Lawn W, Freeman TP, Pope RA, Joye A, Harvey L, Hindocha C, Mokrysz C, Moss A, Wall MB, Bloomfield MA, Das RK, Morgan CJ, Nutt DJ, and Curran HV
- Subjects
- Administration, Inhalation, Adult, Cannabis, Decision Making drug effects, Depression, Double-Blind Method, Female, Humans, Male, Marijuana Abuse psychology, Marijuana Smoking, Reward, Young Adult, Cannabidiol pharmacology, Cannabinoid Receptor Agonists pharmacology, Choice Behavior drug effects, Dronabinol pharmacology, Learning drug effects, Motivation drug effects
- Abstract
Rationale: Anecdotally, both acute and chronic cannabis use have been associated with apathy, amotivation, and other reward processing deficits. To date, empirical support for these effects is limited, and no previous studies have assessed both acute effects of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as well as associations with cannabis dependence., Objectives: The objectives of this study were (1) to examine acute effects of cannabis with CBD (Cann + CBD) and without CBD (Cann-CBD) on effort-related decision-making and (2) to examine associations between cannabis dependence, effort-related decision-making and reward learning., Methods: In study 1, 17 participants each received three acute vaporized treatments, namely Cann-CBD (8 mg THC), Cann + CBD (8 mg THC + 10 mg CBD) and matched placebo, followed by a 50 % dose top-up 1.5 h later, and completed the Effort Expenditure for Rewards Task (EEfRT). In study 2, 20 cannabis-dependent participants were compared with 20 non-dependent, drug-using control participants on the EEfRT and the Probabilistic Reward Task (PRT) in a non-intoxicated state., Results: Cann-CBD reduced the likelihood of high-effort choices relative to placebo (p = 0.042) and increased sensitivity to expected value compared to both placebo (p = 0.014) and Cann + CBD (p = 0.006). The cannabis-dependent and control groups did not differ on the EEfRT. However, the cannabis-dependent group exhibited a weaker response bias than the control group on the PRT (p = 0.007)., Conclusions: Cannabis acutely induced a transient amotivational state and CBD influenced the effects of THC on expected value. In contrast, cannabis dependence was associated with preserved motivation alongside impaired reward learning, although confounding factors, including depression, cannot be disregarded. This is the first well powered, fully controlled study to objectively demonstrate the acute amotivational effects of THC., Competing Interests: Compliance with ethical standards The study was approved by the UCL ethics committee, all participants provided written informed consent and the study was conducted in accordance with the Declaration of Helsinki. Funding Study 1 was funded by Drug Science. The cannabis used in study 1 was bought from Bedrocan (Veendam, thew Netherlands). Study 2 was funded by WL’s PhD grant from the BBSRC and University College London. Conflicts of interest HVC is a member of the UK MRC boards and Drug Science. DJN is an advisor to the British National Formulary, MRC, GMC, Department of Health; President of European Brain Council; Past President of British Neuroscience Association and European College of Neuropsychopharmacology, Chair of Drug Science (UK); Member of International Centre for Science in Drug Policy; Advisor to Swedish government on drug, alcohol, and tobacco research; editor of the Journal of Psychopharmacology; Member of Advisory Boards of Lundbeck, MSD, Nalpharm, Orexigen, Shire, MSD; has received speaking honoraria (in addition to above) from BMS/Otsuka, GSK, Lilly, Janssen, Servier, AZ, and Pfizer; is a member of the Lundbeck International Neuroscience Foundation; has received grants or clinical trial payments from P1vital, MRC, NHS, Lundbeck, RB; has share options in P1vital; has been an expert witness in a number of legal cases relating to psychotropic drugs; and has edited/written 27 books, some purchased by pharma companies. CJAM has consulted for Janssen and GlaxoSmithKline and received compensation. MBW is employed by Imanova Ltd., a private company that performs contract research work for the pharmaceutical industry. The authors declare that they have no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
15. Schizophrenia: inorganic no more.
- Author
-
Bloomfield MA, Buck SC, and Howes OD
- Subjects
- Humans, International Classification of Diseases, Schizophrenia classification
- Published
- 2016
- Full Text
- View/download PDF
16. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.
- Author
-
Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, Waldman A, Turkheimer FE, Egerton A, Stone J, and Howes OD
- Subjects
- Adult, Chronic Disease, Drug Resistance, Female, Humans, Male, Middle Aged, Antipsychotic Agents pharmacology, Glutamic Acid metabolism, Gyrus Cinguli metabolism, Proton Magnetic Resonance Spectroscopy methods, Schizophrenia drug therapy, Schizophrenia metabolism
- Abstract
Introduction: Resistance to antipsychotic treatment is a significant clinical problem in patients with schizophrenia with approximately 1 in 3 showing limited or no response to repeated treatments with antipsychotic medication. The neurobiological basis for treatment resistance is unknown but recent evidence implicates glutamatergic function in the anterior cingulate cortex. We examined glutamate levels of chronically ill treatment-resistant patients directly compared to treatment-responsive patients., Methods: We acquired proton magnetic resonance spectroscopy (1H-MRS) at 3 Tesla from 21 treatment-resistant and 20 treatment-responsive patients. All participants had a DSM-IV diagnosis of schizophrenia. Treatment-resistant patients were classified using the modified Kane criteria. The groups were matched for age, sex, smoking status, and illness duration., Results: Glutamate to creatine ratio levels were higher in treatment-resistant patients (Mean [SD] = 1.57 [0.24]) than in treatment-responsive patients (Mean[SD] = 1.38 [0.23]), (T[35] = 2.34, P = .025, 2-tailed), with a large effect size of d = 0.76. A model assuming 2 populations showed a 25% improvement in the fit of the Akaike weights (0.55) over a model assuming 1 population (0.44), producing group values almost identical to actual group means., Discussion: Increased anterior cingulate glutamate level is associated with treatment-resistant schizophrenia. This appears to be a stable neurobiological trait of treatment-resistant patients. We discuss possible explanations for glutamatergic dysfunction playing a significant role in resistance to conventional antipsychotic treatments, which are all dopamine-2 receptor blockers. Our findings suggest that glutamatergic treatments may be particularly effective in resistant patients and that 1H-MRS glutamate indices can potentially have clinical use., (© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
17. Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review.
- Author
-
Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, and Baler R
- Subjects
- Adult, Humans, Legislation, Drug, Marijuana Abuse complications, United States, Behavior drug effects, Cannabis adverse effects, Cognition drug effects, Marijuana Abuse psychology, Motivation drug effects, Psychoses, Substance-Induced etiology
- Abstract
With a political debate about the potential risks and benefits of cannabis use as a backdrop, the wave of legalization and liberalization initiatives continues to spread. Four states (Colorado, Washington, Oregon, and Alaska) and the District of Columbia have passed laws that legalized cannabis for recreational use by adults, and 23 others plus the District of Columbia now regulate cannabis use for medical purposes. These policy changes could trigger a broad range of unintended consequences, with profound and lasting implications for the health and social systems in our country. Cannabis use is emerging as one among many interacting factors that can affect brain development and mental function. To inform the political discourse with scientific evidence, the literature was reviewed to identify what is known and not known about the effects of cannabis use on human behavior, including cognition, motivation, and psychosis.
- Published
- 2016
- Full Text
- View/download PDF
18. Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.
- Author
-
Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, Bloomfield MA, Bonoldi I, Kalk N, Turkheimer F, McGuire P, de Paola V, and Howes OD
- Subjects
- Adult, Brain Mapping methods, Female, Genetic Testing, Gray Matter metabolism, Gray Matter pathology, Gray Matter physiopathology, Humans, Male, Neuroimmunomodulation, Positron-Emission Tomography methods, Prognosis, Psychotic Disorders metabolism, Psychotic Disorders physiopathology, Receptors, GABA genetics, Reproducibility of Results, Risk Assessment methods, Microglia metabolism, Microglia pathology, Psychotic Disorders diagnosis, Schizophrenia diagnosis, Schizophrenia etiology, Schizophrenia metabolism, Schizophrenia physiopathology
- Abstract
Objective: The purpose of this study was to determine whether microglial activity, measured using translocator-protein positron emission tomography (PET) imaging, is increased in unmedicated persons presenting with subclinical symptoms indicating that they are at ultra high risk of psychosis and to determine whether microglial activity is elevated in schizophrenia after controlling for a translocator-specific genetic polymorphism., Method: The authors used the second-generation radioligand [(11)C]PBR28 and PET to image microglial activity in the brains of participants at ultra high risk for psychosis. Participants were recruited from early intervention centers. The authors also imaged a cohort of patients with schizophrenia and matched healthy subjects for comparison. In total, 50 individuals completed the study. At screening, participants were genotyped to account for the rs6971 polymorphism in the gene encoding the 18Kd translocator protein. The main outcome measure was total gray matter [(11)C]PBR28 binding ratio, representing microglial activity., Results: [(11)C]PBR28 binding ratio in gray matter was elevated in ultra-high-risk participants compared with matched comparison subjects (Cohen's d >1.2) and was positively correlated with symptom severity (r=0.730). Patients with schizophrenia also demonstrated elevated microglial activity relative to matched comparison subjects (Cohen's d >1.7)., Conclusions: Microglial activity is elevated in patients with schizophrenia and in persons with subclinical symptoms who are at ultra high risk of psychosis and is related to at-risk symptom severity. These findings suggest that neuroinflammation is linked to the risk of psychosis and related disorders, as well as the expression of subclinical symptoms.
- Published
- 2016
- Full Text
- View/download PDF
19. The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity.
- Author
-
Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B, Williams LT, Roseman L, Brugger S, De Meer I, Tanner M, Tyacke R, Wolff K, Sethi A, Bloomfield MA, Williams TM, Bolstridge M, Stewart L, Morgan C, Newbould RD, Feilding A, Curran HV, and Nutt DJ
- Subjects
- Adult, Cerebrovascular Circulation drug effects, Double-Blind Method, Female, Healthy Volunteers, Hippocampus drug effects, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prefrontal Cortex drug effects, Temporal Lobe drug effects, Young Adult, Affect physiology, Amygdala drug effects, N-Methyl-3,4-methylenedioxyamphetamine administration & dosage, Oxygen blood, Serotonin Agents administration & dosage
- Abstract
Background: The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in most individuals., Methods: In a double-blind, placebo-controlled, balanced-order study, MDMA was orally administered to 25 physically and mentally healthy individuals. Arterial spin labeling and seed-based resting state functional connectivity (RSFC) were used to produce spatial maps displaying changes in cerebral blood flow (CBF) and RSFC after MDMA administration. Participants underwent two arterial spin labeling and two blood oxygen level-dependent scans in a 90-minute scan session; MDMA and placebo study days were separated by 1 week., Results: Marked increases in positive mood were produced by MDMA. Decreased CBF only was observed after MDMA, and this was localized to the right medial temporal lobe (MTL), thalamus, inferior visual cortex, and the somatosensory cortex. Decreased CBF in the right amygdala and hippocampus correlated with ratings of the intensity of global subjective effects of MDMA. The RSFC results complemented the CBF results, with decreases in RSFC between midline cortical regions, the medial prefrontal cortex, and MTL regions, and increases between the amygdala and hippocampus. There were trend-level correlations between these effects and ratings of intense and positive subjective effects., Conclusions: The MTLs appear to be specifically implicated in the mechanism of action of MDMA, but further work is required to elucidate how the drug's characteristic subjective effects arise from its modulation of spontaneous brain activity., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
20. Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms.
- Author
-
McCutcheon R, Beck K, Bloomfield MA, Marques TR, Rogdaki M, and Howes OD
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Antipsychotic Agents administration & dosage, Antipsychotic Agents blood, Drug Resistance physiology, Schizophrenia blood, Schizophrenia drug therapy
- Abstract
A large proportion of individuals with schizophrenia show an inadequate response to treatment with antipsychotics. It can be unclear whether this is secondary to subtherapeutic antipsychotic plasma levels or to medication ineffectiveness. The purpose of the present study was to determine the extent of subtherapeutic antipsychotic plasma levels in a group of patients clinically identified as treatment-resistant. In addition we investigated the frequency of antipsychotic plasma level monitoring in standard clinical practice. Antipsychotic plasma levels were measured in 36 patients identified as having treatment-resistant schizophrenia by their treating clinicians. Sixteen (44%) patients showed either undetectable (19%) or subtherapeutic levels (25%), and 20 (56%) patients had levels in the therapeutic range. Subtherapeutic plasma levels were significantly associated with black ethnicity, shorter duration of current treatment and antipsychotics other than olanzapine and amisulpride. Antipsychotic plasma levels had been measured in only one patient in the year prior to our study. We found over one-third of patients identified as treatment-resistant have subtherapeutic antipsychotic levels. This indicates that they may be under-treated rather than treatment-resistant, and thus should receive different management. Currently the measurement of antipsychotic levels may be under-utilised., (© The Author(s) 2015.)
- Published
- 2015
- Full Text
- View/download PDF
21. Prevalence of serum N-methyl-D-aspartate receptor autoantibodies in refractory psychosis.
- Author
-
Beck K, Lally J, Shergill SS, Bloomfield MA, MacCabe JH, Gaughran F, and Howes OD
- Subjects
- Adult, Aged, Antipsychotic Agents therapeutic use, Female, Humans, Male, Middle Aged, Psychotic Disorders blood, Psychotic Disorders drug therapy, Young Adult, Autoantibodies blood, Autoantibodies immunology, Drug Resistance, Psychotic Disorders immunology, Receptors, N-Methyl-D-Aspartate immunology
- Abstract
N-methyl-d-aspartate receptor (NMDA-R) autoantibodies have been reported in people with acute psychosis. We hypothesised that their presence may be implicated in the aetiology of treatment-refractory psychosis. We sought to ascertain the point prevalence of NMDA-R antibody positivity in patients referred to services for treatment-refractory psychosis. We found that 3 (7.0%) of 43 individuals had low positive NMDA-R antibody titres. This suggests that NMDA-R autoantibodies are unlikely to account for a large proportion of treatment-refractory psychosis., (Royal College of Psychiatrists.)
- Published
- 2015
- Full Text
- View/download PDF
22. Commentary on a study of the prevalence of mental disorders by Breslau et al.
- Author
-
Bloomfield MA, Jauhar S, Froudist-Walsh S, Bonoldi I, and Howes OD
- Subjects
- Female, Humans, Male, Depressive Disorder, Major epidemiology, Mental Disorders epidemiology, Rural Population, Urban Population
- Published
- 2015
- Full Text
- View/download PDF
23. The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach.
- Author
-
Beck K, McCutcheon R, Bloomfield MA, Gaughran F, Reis Marques T, MacCabe J, Selvaraj S, Taylor D, and Howes OD
- Subjects
- Adult, Disease Management, Female, Humans, Male, Middle Aged, Treatment Failure, Antipsychotic Agents therapeutic use, Clozapine therapeutic use, Community Mental Health Services methods, Psychotic Disorders drug therapy, Schizophrenia drug therapy
- Abstract
Objective: To describe a practical approach to the community management of treatment-resistant schizophrenia (TRS)., Method: A descriptive review of an approach to the assessment and management of patients with TRS, including the community titration of clozapine treatment, and a report of the management recommendations for the first one hundred patients assessed by the Treatment REview and Assessment Team (TREAT)., Results: The standardized model for the community assessment, management and titration of clozapine is described. To date, 137 patients have been referred to this service and 100 patients (72%) attended for assessment. Of these, 33 have been initiated on clozapine while fifteen have had clozapine recommended but have not wished to undertake clozapine treatment. Other management options recommended have included augmentation strategies and long-acting injectable antipsychotics., Conclusion: The service had increased the number of patients receiving community assessment and initiation of clozapine by five-fold relative to the rate prior to the establishment of the service. The large number of referrals and high attendance rate indicates that there is clinical demand for the model. Systematic evaluation is required to determine the clinical and cost-effectiveness of this model and its potential application to other clinical settings., (© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
24. Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study.
- Author
-
Bloomfield MA, Pepper F, Egerton A, Demjaha A, Tomasi G, Mouchlianitis E, Maximen L, Veronese M, Turkheimer F, Selvaraj S, and Howes OD
- Subjects
- Adult, Case-Control Studies, Corpus Striatum diagnostic imaging, Dihydroxyphenylalanine analogs & derivatives, Female, Humans, Male, Positron-Emission Tomography, Radiopharmaceuticals, Surveys and Questionnaires, Tobacco Use Disorder diagnostic imaging, Corpus Striatum metabolism, Dopamine metabolism, Smoking metabolism, Tobacco Use Disorder metabolism
- Abstract
Tobacco addiction is a global public health problem. Addiction to tobacco is thought to involve the effects of nicotine on the dopaminergic system. Only one study has previously investigated dopamine synthesis capacity in cigarette smokers. This study, exclusively in male volunteers, reported increased dopamine synthesis capacity in heavy smokers compared with non-smokers. We sought to determine whether dopamine synthesis capacity was elevated in a larger sample of cigarette smokers that included females. Dopamine synthesis capacity was measured in 15 daily moderate smokers with 15 sex- and age-matched control subjects who had never smoked tobacco. Dopamine synthesis capacity (indexed as the influx rate constant K(i)(cer)) was measured with positron emission tomography and 3,4-dihydroxy-6-[(18)F]-fluoro-l-phenylalanine. There was no significant group difference in dopamine synthesis capacity between smokers and non-smoker controls in the whole striatum (t28=0.64, p=0.53) or any of its functional subdivisions. In smokers, there were no significant relationships between the number of cigarettes smoked per day and dopamine synthesis capacity in the whole striatum (r=-0.23, p=0.41) or any striatal subdivision. These findings indicate that moderate smoking is not associated with altered striatal dopamine synthesis capacity.
- Published
- 2014
- Full Text
- View/download PDF
25. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.
- Author
-
Bloomfield MA, Morgan CJ, Kapur S, Curran HV, and Howes OD
- Subjects
- Apathy drug effects, Brain diagnostic imaging, Brain Mapping, Cannabis, Cohort Studies, Corpus Striatum diagnostic imaging, Corpus Striatum physiopathology, Dihydroxyphenylalanine, Female, Fluorine Radioisotopes, Humans, Male, Positron-Emission Tomography, Psychiatric Status Rating Scales, Radiopharmaceuticals, Self Report, Young Adult, Apathy physiology, Brain physiopathology, Dopamine metabolism, Marijuana Abuse diagnostic imaging, Marijuana Abuse physiopathology
- Abstract
Rationale: Cannabis is the most widely used illicit drug in the world, and regular use has been associated with reduced motivation, i.e. apathy. Regular long-term cannabis use has been associated with reduced dopamine synthesis capacity. The mesolimbic dopaminergic system mediates the processing of incentive stimuli by modifying their motivational value, which in turn is modulated by endocannabinoid signalling. Thus, it has been proposed that dopaminergic dysfunction underlies the apathy associated with chronic cannabis use., Objectives: The aim of this study was to examine the relationship between dopaminergic function and subjective apathy in cannabis users., Methods: We measured dopamine synthesis capacity (indexed as the influx rate constant K i(cer)) via 3,4-dihydroxy-6-[(18)F]-fluoro-l-phenylalanine positron emission tomography and subjective apathy using the self-rated Apathy Evaluation Scale (AES-S) in 14 regular cannabis users., Results: All subjects scored in excess of 34 points on the AES-S (median [interquartile range] 59.5 [7.5]), indicative of significant apathy based on normative data. K i (cer) was inversely correlated to AES-S score in the whole striatum and its associative functional subdivision (Spearman's rho = -0.64, p = 0.015 [whole striatum]; rho = -0.69, p = 0.006 [associative]) but not in the limbic or sensorimotor striatal subdivisions. There were no significant relationships between AES-S and current cannabis consumption (rho = 0.28, p = 0.34) or age of first cannabis use (rho = 0.25, p = 0.40)., Conclusions: These findings indicate that the reduction in striatal dopamine synthesis capacity associated with chronic cannabis use may underlie reduced reward sensitivity and a motivation associated with chronic cannabis use.
- Published
- 2014
- Full Text
- View/download PDF
26. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.
- Author
-
Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, and Howes OD
- Subjects
- Case-Control Studies, Corpus Striatum diagnostic imaging, Corpus Striatum drug effects, Corpus Striatum metabolism, Dihydroxyphenylalanine analogs & derivatives, Female, Functional Neuroimaging, Humans, Male, Marijuana Abuse diagnostic imaging, Positron-Emission Tomography, Psychoses, Substance-Induced diagnostic imaging, Young Adult, Cannabis adverse effects, Dopamine biosynthesis, Dopaminergic Neurons drug effects, Dopaminergic Neurons metabolism, Marijuana Abuse metabolism, Psychoses, Substance-Induced metabolism
- Abstract
Background: Cannabis is the most widely used illicit drug globally, and users are at increased risk of mental illnesses including psychotic disorders such as schizophrenia. Substance dependence and schizophrenia are both associated with dopaminergic dysfunction. It has been proposed, although never directly tested, that the link between cannabis use and schizophrenia is mediated by altered dopaminergic function., Methods: We compared dopamine synthesis capacity in 19 regular cannabis users who experienced psychotic-like symptoms when they consumed cannabis with 19 nonuser sex- and age-matched control subjects. Dopamine synthesis capacity (indexed as the influx rate constant [Formula: see text] ) was measured with positron emission tomography and 3,4-dihydroxy-6-[(18)F]-fluoro-l-phenylalanine ([(18)F]-DOPA)., Results: Cannabis users had reduced dopamine synthesis capacity in the striatum (effect size: .85; t36 = 2.54, p = .016) and its associative (effect size: .85; t36 = 2.54, p = .015) and limbic subdivisions (effect size: .74; t36 = 2.23, p = .032) compared with control subjects. The group difference in dopamine synthesis capacity in cannabis users compared with control subjects was driven by those users meeting cannabis abuse or dependence criteria. Dopamine synthesis capacity was negatively associated with higher levels of cannabis use (r = -.77, p < .001) and positively associated with age of onset of cannabis use (r = .51, p = .027) but was not associated with cannabis-induced psychotic-like symptoms (r = .32, p = .19)., Conclusions: These findings indicate that chronic cannabis use is associated with reduced dopamine synthesis capacity and question the hypothesis that cannabis increases the risk of psychotic disorders by inducing the same dopaminergic alterations seen in schizophrenia., (Copyright © 2014 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
27. Does human presynaptic striatal dopamine function predict social conformity?
- Author
-
Stokes PR, Benecke A, Puraite J, Bloomfield MA, Shotbolt P, Reeves SJ, Lingford-Hughes AR, Howes O, and Egerton A
- Subjects
- Adult, Corpus Striatum diagnostic imaging, Humans, Male, Middle Aged, Personality Assessment, Presynaptic Terminals diagnostic imaging, Radionuclide Imaging, Social Conformity, Young Adult, Corpus Striatum metabolism, Dopamine metabolism, Personality, Presynaptic Terminals metabolism, Receptors, Dopamine D2 metabolism
- Abstract
Socially desirable responding (SDR) is a personality trait which reflects either a tendency to present oneself in an overly positive manner to others, consistent with social conformity (impression management (IM)), or the tendency to view one's own behaviour in an overly positive light (self-deceptive enhancement (SDE)). Neurochemical imaging studies report an inverse relationship between SDR and dorsal striatal dopamine D₂/₃ receptor availability. This may reflect an association between SDR and D₂/₃ receptor expression, synaptic dopamine levels or a combination of the two. In this study, we used a [¹⁸F]-DOPA positron emission tomography (PET) image database to investigate whether SDR is associated with presynaptic dopamine function. Striatal [¹⁸F]-DOPA uptake, (k(i)(cer), min⁻¹), was determined in two independent healthy participant cohorts (n=27 and 19), by Patlak analysis using a cerebellar reference region. SDR was assessed using the revised Eysenck Personality Questionnaire (EPQ-R) Lie scale, and IM and SDE were measured using the Paulhus Deception Scales. No significant associations were detected between Lie, SDE or IM scores and striatal [¹⁸F]-DOPA k(i)(cer). These results indicate that presynaptic striatal dopamine function is not associated with social conformity and suggests that social conformity may be associated with striatal D₂/₃ receptor expression rather than with synaptic dopamine levels.
- Published
- 2014
- Full Text
- View/download PDF
28. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort.
- Author
-
Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P, McGuire PK, and Howes OD
- Subjects
- Adult, Basal Ganglia diagnostic imaging, Cohort Studies, Corpus Striatum diagnostic imaging, Dihydroxyphenylalanine analogs & derivatives, Female, Humans, Male, Presynaptic Terminals chemistry, Prodromal Symptoms, Psychotic Disorders diagnosis, Radionuclide Imaging, Risk Factors, Young Adult, Dopamine biosynthesis, Presynaptic Terminals diagnostic imaging, Psychotic Disorders diagnostic imaging
- Abstract
Background: Using positron emission tomography (PET), we previously observed increases in 3,4-dihydroxy-6-[(18)F]fluoro-L-phenylalanine ((18)F-DOPA) uptake in the striatum of subjects at ultra-high risk (UHR) for psychosis, indicating elevated presynaptic dopamine synthesis capacity. The purpose of this study was to test if this finding would be replicated in a second UHR cohort., Methods: (18)F-DOPA PET was used to estimate dopamine synthesis capacity in the striatum of an entirely new cohort of 26 individuals at UHR for psychosis (14 males, mean±SD age = 22.7±4.7 years) and 20 healthy volunteers matched for age and gender (11 males, mean±SD age = 24.5±4.5 years)., Results: Dopamine synthesis capacity was elevated in the whole [t(44) = 2.6; p = .01, effect size = .81] and associative striatum [t(44) = 2.6; p = .01, effect size = .73] of UHR compared with control subjects. When the two samples were combined to give a final sample of 32 control and 50 UHR subjects, the higher levels of dopamine synthesis capacity in the UHR group reached significance across the whole [F(1,81) = 11.0; p = .001], associative [F(1,81) = 12.7; p = .001], and sensorimotor [F(1,81) = 4.7; p = .03], but not the limbic [F(1,81) = 2.1; p = .2], striatum., Conclusions: The findings indicate that elevated dopamine synthesis capacity in the dorsal striatum is a robust feature of individuals at UHR for psychosis and provide further evidence that dopaminergic abnormalities precede the onset of psychosis., (Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
29. Letter: Fee schedules and workloads.
- Author
-
Bloomfield MA
- Subjects
- Canada, Fee Schedules, Fees, Medical, Work
- Published
- 1975
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.